Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Taipei City Hospital
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06244550CT.gov Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fibrotic Liver Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Metformin (this asset) | Taipei City Hospital | N/A | D · 30 |
| Entecavir | Tanta University | P4 | BB |
| Colchicinum | Zagazig University | P4 | BB |
| Peg-Intron | Beth Israel Deaconess Medical Center | P4 | BB |
| Peg-Ifn | Beijing Friendship Hospital | P4 | BB |
| Ribavirin | ANRS, Emerging Infectious Diseases | P3 | BB |
| A Therapeutic Pegylated Fibroblast Growth Factor 21 Agonist/Mimetic Which Restores Leptin Responsiveness | Bristol-Myers Squibb | P2 | BB |
| Hydronidone | Beijing Continent Pharmaceutical Co, Ltd. | P3 | BB |
| Losartan | Hospital Clinic of Barcelona | P4 | BB |
+42 more in the Fibrotic Liver Disease cohort
Other indications for Metformin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prediabetes Syndrome | — | P4 | A · 81 |
| Gestational Diabetes | — | P4 | A · 81 |
| Diabetes Mellitus | — | P4 | A · 80 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Metformin in Fibrotic Liver Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/metformin-fibrotic-liver-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →